Indivior Responds to Publication of a Letter by Oaktree Capital Management to the Board of Indivior Richmond, VA

Indivior Responds to Publication

of a Letter by Oaktree Capital Management to the Board of

Richmond, VA, November 8, 2024 - Indivior PLC (NASDAQ / LSE: INDV)

the Board of Directors (the

"Board") of Indivior plc ("Indivior" or the "Company") notes the

publication today of a letter from Oaktree Capital Management LP

("Oaktree") to the Board of Indivior.

The Board has engaged actively with Oaktree in recent weeks on

these topics, and remains open-minded about all proposals to

enhance value creation. The Board is focused on acting in the best

interests of all shareholders as we continue to execute on our

Indivior looks forward to further engagement with

Oaktree and other shareholders.

Indivior is a global pharmaceutical company working to help change

patients' lives by developing medicines to treat substance use

disorders (SUD), overdose and serious mental illnesses. Our vision

is that all patients around the world will have access to

evidence-based treatment for the chronic conditions and

co-occurring disorders of SUD. Indivior is dedicated to

transforming SUD from a global human crisis to a recognized and

treated chronic disease. Building on its global portfolio of OUD

treatments, Indivior has a pipeline of product candidates designed

to both expand on its heritage in this category and potentially

address other chronic conditions and co-occurring disorders of SUD.

Headquartered in the United States in Richmond, VA, Indivior

employs over 1,000 individuals globally and its portfolio of

products is available in over 30 countries worldwide.

Visit www.indivior.com to

learn more. Connect with Indivior on LinkedIn by

visiting www.linkedin.com/company/indivior.

For Further Information